- Viking Therapeutics recently reported third quarter 2026 results, with a net loss of US$183.19 million and a basic loss per share from continuing operations of US$1.55. The company also plans to present new VK2735 obesity data at ObesityWeek 2026 and the Stifel 2026 Healthcare Conference.
- The combination of deeper VK2735 clinical readouts and widening losses highlights how Viking Therapeutics is focusing heavily on obesity drug development while absorbing substantial research and operating costs before any revenue arrives.
- Upcoming VK2735 poster presentations at ObesityWeek may influence how investors evaluate the longer term investment narrative for Viking Therapeutics.
Viking Therapeutics Investment Narrative Recap
To own Viking Therapeutics, you need to be comfortable backing a clinical stage specialist that is still loss making and fully tied to obesity and metabolic drug development. The analyst consensus Narrative on Simply Wall St highlights how everything hinges on VK2735 and related programs eventually moving from trials to commercial use. The latest quarterly net loss of US$183.19 million reinforces that the business is still firmly in cash burn mode.
In the short term, the main operational catalyst is progress and data from the VANQUISH Phase 3 VK2735 trials, including any clarity on timelines and regulatory dialogue. The biggest risk remains trial setbacks or safety issues, which could extend the loss making period and increase dilution pressure. The recent earnings and guidance do not appear to materially change that core risk reward setup.
The ObesityWeek 2026 posters on VK2735 are the clearest near term operational event tied to this earnings update. Management plans to show Phase 3 VANQUISH 2 baseline characteristics alongside Phase 2 VENTURE data on obesity severity and cardiometabolic markers. For a business with no current revenue, that level of detail helps investors judge how mature the lead asset really is.
For you as a shareholder, the interest is less about conference visibility and more about whether these data deepen confidence in the ongoing VANQUISH studies as the key catalyst. Any read through on tolerability, adherence or cardiometabolic effects helps you weigh the competitive threat from other GLP 1 and oral options, as flagged in the analyst consensus Narrative on Simply Wall St as a central risk to Viking Therapeutics.
Viking Therapeutics Long Term Growth Assumptions
Viking Therapeutics sits in a rare spot. There is no revenue today, yet analyst models already plug in a future top line of US$118.5 million by 2029, tied almost entirely to obesity treatments. Consensus work on Simply Wall St assumes the business eventually reaches a profit margin in line with the broader US biotech group at 10.9%, which would lift earnings from a loss of US$359.6 million today to a projected profit of US$12.9 million by 2029.
On those inputs, the implied earnings swing is very large in both value and direction. Moving from a sizeable loss into a modest profit means analysts are effectively underwriting a multi hundred million dollar improvement in the income statement. Since the revenue base is modeled to move from zero to US$118.5 million in the same period, that scenario also bakes in a rapid ramp in obesity drug sales once VK2735 or related assets start to generate commercial demand.
Viking Therapeutics' narrative projects US$118.5 million revenue and US$12.9 million earnings by 2029. This requires a move from zero to US$118.5 million in yearly revenue and an earnings increase of roughly US$372.5 million from a loss of US$359.6 million today.
To translate those fundamentals into a valuation, analysts assume the stock would trade on a P/E multiple of 1,109.1x in 2029 if those profits arrive, compared with a current P/E of 10.3x in loss territory and an industry reference point of 21.6x. That future multiple is very high relative to typical biotech levels, which means a lot of the implied upside in the models rests on investors assigning premium pricing to even early stage profitability.
The Simply Wall St framework pulls these moving parts together through a discount rate of about 7.1% and lands on a consensus target price of US$92.72. Individual analyst views spread widely, from US$35 on the low end to US$125 at the high end, which shows how sensitive the debate is around timing, trial outcomes, and eventual share of the obesity treatment market. With the current share price referenced at US$32.14, the gap to the average target is described as 65.3% higher, although that spread only holds if you accept the revenue, margin and P/E assumptions underpinning the model.
Uncover why Viking Therapeutics' fair value indicates a 224% potential upside to its current price, which could narrow quickly.
Exploring Other Perspectives
These fresh Viking Therapeutics updates land against a far more optimistic alternate storyline built around future pricing power. The most bullish analysts were sketching out about US$1.3b in revenue and US$214.5 million in earnings by 2029. That is a huge stretch from today’s losses, and it shows how sharply views can diverge. Treat the ObesityWeek and Stifel appearances as chances to test which narrative feels closer to your own expectations, knowing both sets of forecasts were built before this news and may evolve from here.
Explore 3 other Viking Therapeutics fair value estimates, including one that suggests potential upside of up to 233% from the current price.
Decide For Yourself
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Viking Therapeutics research is our analysis highlighting 3 important warning signs that could impact your investment decision.
- See our latest analysis for Viking Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Viking Therapeutics' overall financial health at a glance.
Looking For More Investment Ideas Beyond Viking Therapeutics?
If the Viking Therapeutics story has you thinking about position sizing and portfolio balance, it can help to line it up against other opportunities with very different risk profiles. You can use the Simply Wall St Screener to build that comparison set in a few minutes and pressure test whether this obesity focused biotech really deserves space alongside steadier, cash generative businesses.
- For investors who want quality and value working together, scan a curated 35 high quality undervalued stocks that combine solid fundamentals with attractive pricing.
- If capital preservation is front of mind, filter for 30 resilient stocks with low risk scores that score well on financial strength and volatility.
- When you are hunting for future compounders early, sort through a focused 20 high quality undiscovered gems that many portfolios may not yet hold.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com